General Dermatology

Elyse Love, MD, discusses the role of the program in supporting students with skin conditions the financial support and empowerment necessary for academic success.

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.

The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.

A recent reviewed showed that self-stigma in patients with skin disease is influenced by body image issues and social support.

New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.

These positive data will support US regulatory submission by end of 2024.

Researchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.

Researchers reported that second-year students were more likely to identify dermatological conditions, particularly in White patients.

It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.

A recent study investigated the acceptability, barriers, and facilitators associated with digital health tools.

New research shows the 675-nm laser enhances skin texture and rejuvenation, making it a valuable tool for various dermatological conditions.

Citius' recently-approved Lymphir has been added to the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology.

The phase 2 trial for EVO756, targeting mast cell-related CIndU, is now underway at 15 US study sites.

Dermatology Times is looking back on the top stories in dermatology from the month of August.

Dermatology Times is recapping our top expert interviews from the month of August.

Researchers observed significant improvements in roughness and redness in patients treated with the non-cross-linked compound.

A recent review highlighted how AI can be used to enhance diagnostic accuracy, consultations, treatment planning, and patient education.

The findings support the idea that Botox can enhance emotional well-being and self-confidence, although it did not notably impact the quality of life.

Bullous pemphigoid in youth is rare and can be missed due to negative BP180 ELISA results, complicating timely diagnosis in children.